Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT07489573
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Hidradenitis Suppurativa (HS)
Interventions
DRUG:
Secukinumab
Sponsor
Novartis Pharmaceuticals